These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 18419350

  • 1. Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy.
    Hulgan T, Tebas P, Canter JA, Mulligan K, Haas DW, Dubé M, Grinspoon S, Robbins GK, Motsinger AA, Kallianpur AR, AIDS Clinical Trials Group 384 and A5005s Study Teams.
    J Infect Dis; 2008 Mar 15; 197(6):858-66. PubMed ID: 18419350
    [Abstract] [Full Text] [Related]

  • 2. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142.
    Hulgan T, Haubrich R, Riddler SA, Tebas P, Ritchie MD, McComsey GA, Haas DW, Canter JA.
    AIDS; 2011 Jan 02; 25(1):37-47. PubMed ID: 20871389
    [Abstract] [Full Text] [Related]

  • 3. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
    Dubé MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, Roubenoff R, Tebas P, Adult Clinical Trials Group 384.
    J Acquir Immune Defic Syndr; 2007 Aug 15; 45(5):508-14. PubMed ID: 17589373
    [Abstract] [Full Text] [Related]

  • 4. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH, Hassink EA, van Eck-Smit BL, Borleffs JC, Lange JM, Reiss P.
    HIV Clin Trials; 2007 Aug 15; 8(5):337-44. PubMed ID: 17956835
    [Abstract] [Full Text] [Related]

  • 5. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study.
    Hulgan T, Haas DW, Haines JL, Ritchie MD, Robbins GK, Shafer RW, Clifford DB, Kallianpur AR, Summar M, Canter JA.
    AIDS; 2005 Sep 02; 19(13):1341-9. PubMed ID: 16103764
    [Abstract] [Full Text] [Related]

  • 6. Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.
    Dubé MP, Parker RA, Mulligan K, Tebas P, Robbins GK, Roubenoff R, Grinspoon SK.
    Clin Infect Dis; 2007 Jul 01; 45(1):120-6. PubMed ID: 17554712
    [Abstract] [Full Text] [Related]

  • 7. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy.
    Kallianpur AR, Hulgan T, Canter JA, Ritchie MD, Haines JL, Robbins GK, Shafer RW, Clifford DB, Haas DW.
    AIDS; 2006 Jul 13; 20(11):1503-13. PubMed ID: 16847405
    [Abstract] [Full Text] [Related]

  • 8. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.
    Dubé MP, Parker RA, Tebas P, Grinspoon SK, Zackin RA, Robbins GK, Roubenoff R, Shafer RW, Wininger DA, Meyer WA, Snyder SW, Mulligan K.
    AIDS; 2005 Nov 04; 19(16):1807-18. PubMed ID: 16227788
    [Abstract] [Full Text] [Related]

  • 9. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
    Sutinen J, Walker UA, Sevastianova K, Klinker H, Häkkinen AM, Ristola M, Yki-Järvinen H.
    Antivir Ther; 2007 Nov 04; 12(1):97-105. PubMed ID: 17503753
    [Abstract] [Full Text] [Related]

  • 10. Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection.
    McComsey GA, Libutti DE, O'Riordan M, Shelton JM, Storer N, Ganz J, Jasper J, Harrill D, Gerschenson M.
    Antivir Ther; 2008 Nov 04; 13(5):715-22. PubMed ID: 18771055
    [Abstract] [Full Text] [Related]

  • 11. Contribution of genetic background and antiretroviral therapy to body fat changes in antiretroviral-naive HIV-infected adults.
    Egaña-Gorroño L, Martínez E, Pérez I, Escribà T, Domingo P, Gatell JM, Arnedo M.
    J Antimicrob Chemother; 2014 Nov 04; 69(11):3076-84. PubMed ID: 25185137
    [Abstract] [Full Text] [Related]

  • 12. Mitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapy.
    Hendrickson SL, Kingsley LA, Ruiz-Pesini E, Poole JC, Jacobson LP, Palella FJ, Bream JH, Wallace DC, O'Brien SJ.
    J Acquir Immune Defic Syndr; 2009 Jun 01; 51(2):111-6. PubMed ID: 19339895
    [Abstract] [Full Text] [Related]

  • 13. Higher iron stores and the HFE 187C>G variant delay onset of peripheral neuropathy during combination antiretroviral therapy.
    Kallianpur AR, Wen W, Erwin AL, Clifford DB, Hulgan T, Robbins GK.
    PLoS One; 2020 Jun 01; 15(10):e0239758. PubMed ID: 33057367
    [Abstract] [Full Text] [Related]

  • 14. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
    Feeney ER, van Vonderen MG, Wit F, Danner SA, van Agtmael MA, Villarroya F, Domingo P, Capeau J, Reiss P, Mallon PW, MEDICLAS, NECATT study groups.
    AIDS; 2012 Nov 13; 26(17):2165-74. PubMed ID: 22874517
    [Abstract] [Full Text] [Related]

  • 15. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.
    van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, Gazille C, Zachariah R.
    Trans R Soc Trop Med Hyg; 2007 Aug 13; 101(8):793-8. PubMed ID: 17467756
    [Abstract] [Full Text] [Related]

  • 16. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy.
    Zanone Poma B, Riva A, Nasi M, Cicconi P, Broggini V, Lepri AC, Mologni D, Mazzotta F, Monforte AD, Mussini C, Cossarizza A, Galli M, Icona Foundation Study Group.
    AIDS; 2008 Sep 12; 22(14):1769-78. PubMed ID: 18753860
    [Abstract] [Full Text] [Related]

  • 17. Objective assessment of facial lipoatrophy changes in a cohort of HIV-infected patients taking combination antiretroviral therapy.
    Yang Y, Yap M, Oo Tha N, Paton NI.
    HIV Clin Trials; 2008 Sep 12; 9(6):399-406. PubMed ID: 19203905
    [Abstract] [Full Text] [Related]

  • 18. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E, Miró O, Rodríguez-Santiago B, Garrabou G, Estany C, Masabeu A, Force L, Barrufet P, Cucurull J, Domingo P, Alonso-Villaverde C, Bonjoch A, Morén C, Pérez-Alvarez N, Clotet B, MULTINEKA Study Group.
    Clin Infect Dis; 2009 Sep 15; 49(6):892-900. PubMed ID: 19663689
    [Abstract] [Full Text] [Related]

  • 19. The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.
    Sternfeld T, Schmid M, Tischleder A, Mudra S, Schlamp A, Kost BP, Gruber R, Youle M, Bogner JR, Goebel FD.
    Antivir Ther; 2007 Sep 15; 12(5):769-78. PubMed ID: 17713160
    [Abstract] [Full Text] [Related]

  • 20. Mitochondrial DNA haplogroups and highly active antiretroviral therapy-related lipodystrophy.
    Nasi M, Guaraldi G, Orlando G, Durante C, Pinti M, Nemes E, Nardini G, Passarino G, Cocchi M, Esposito R, Mussini C, Cossarizza A.
    Clin Infect Dis; 2008 Oct 01; 47(7):962-8. PubMed ID: 18752438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.